Start a live chat
1-800-870-4800
Creatine and the heart —
the muscle that cannot rest
and the energy system it runs on.
The heart is, at its most fundamental, a muscle. Not a metaphor for courage or a seat of emotion — a biological pump built from contractile tissue that has been beating continuously since before birth and will not stop until life ends. As a muscle, it has an energy system. And that energy system — the phosphocreatine buffer that smooths the gap between sudden demand and the slower supply of oxidative phosphorylation — is present in cardiac tissue, is regulated independently from skeletal muscle, and declines with age in ways that the sport nutrition framing of creatine has almost entirely missed.
I
Why the heart is different
from every other muscle in the body.
Skeletal muscle is designed for intermittent, variable-intensity work. It contracts forcefully when demanded, rests between contractions, and has metabolic systems — including the phosphocreatine buffer, glycolysis, and oxidative phosphorylation — organized around the assumption that energy demands will fluctuate across a wide range. Skeletal muscle can sprint, rest, walk, and lift in sequences that span orders of magnitude in metabolic rate. It is an intermittent machine.
Cardiac muscle is designed for something fundamentally different: continuous, rhythmic, highly regulated work over a biological lifetime that may span nine decades. The heart contracts approximately 100,000 times per day, every day, without pause. It cannot accumulate an oxygen debt the way skeletal muscle can — there is no resting afterward to repay it. It must extract nearly the maximum available oxygen from the coronary blood supply at rest, leaving very little reserve for demand increases. When cardiac output must increase — during physical exertion, stress, illness, or rapid positional change — the heart meets that demand primarily by beating faster and with greater force, not by switching to alternative metabolic pathways. The energy system of the heart must therefore be organized around continuous high-level function with rapid upward scalability, not around recovery from intermittent exertion.
This fundamental difference in mechanical demand shapes everything about cardiac energy metabolism — including its relationship with creatine. The phosphocreatine system in the heart is not a buffer for explosive athletic effort. It is a buffer for the continuous energy demands of a muscle that must maintain output without pause across decades, and whose energy balance must be maintained with a precision that skeletal muscle never requires. Understanding this distinction is the starting point for understanding why the creatine and aging literature includes a cardiac dimension that the sport nutrition framing of the molecule has largely overlooked. The heart creatine story sits alongside the aging article's multi-tissue picture as one of the more consequential but least-discussed dimensions of creatine biology.
The heart cannot rest between contractions.
It cannot accumulate an oxygen debt.
It must manage energy with a precision
that skeletal muscle never requires —
and it uses creatine to do it.
Cardiac Energy System · Three Pathways
How the heart generates and manages ATP —
and where the phosphocreatine system fits.
Oxidative phosphorylation — the heart's dominant ATP source
Unlike skeletal muscle, which can rely substantially on glycolysis for short-duration high-intensity effort, the heart derives approximately 90–95% of its ATP from oxidative phosphorylation in mitochondria. Cardiac tissue is approximately 30% mitochondria by volume — the highest mitochondrial density of any tissue in the body — reflecting this dependence on aerobic metabolism. The heart's preferred substrates are fatty acids (contributing approximately 60–70% of cardiac ATP in the resting state) and glucose, with lactate, ketone bodies, and amino acids as supplementary sources. The heavy reliance on oxidative phosphorylation means the heart's energy supply is tightly coupled to coronary blood flow and oxygen delivery — and is not available instantly. The gap between the instant demand for contractile force and the finite rate of oxidative ATP production is where the phosphocreatine buffer becomes critical.
Context: cardiac substrate utilization · mitochondrial volume fraction in cardiomyocytes · oxidative phosphorylation rate and cardiac output
The phosphocreatine system — bridging demand spikes and oxidative supply
The cardiac phosphocreatine system serves the same function in the heart that it serves in skeletal muscle — providing immediately available phosphate for ADP rephosphorylation when demand exceeds the rate of oxidative ATP delivery — but the context is different. In skeletal muscle, the phosphocreatine buffer is most relevant during explosive, high-intensity effort. In the heart, it is relevant during every beat — particularly during the rapid upstroke of the cardiac action potential and the peak of systolic contraction when ATP demand spikes sharply. The phosphocreatine-to-ATP ratio in the heart is a well-established index of cardiac energetic status, measurable non-invasively by phosphorus magnetic resonance spectroscopy (³¹P-MRS), and has been studied extensively as a biomarker of cardiac energy metabolism in health and disease. A lower phosphocreatine-to-ATP ratio reflects a heart under greater energetic stress — one whose buffer capacity is reduced relative to its contractile demand.
Context: cardiac phosphocreatine-to-ATP ratio · ³¹P-MRS cardiac energetics research · phosphocreatine buffer and systolic function
The phosphocreatine shuttle — moving energy across the cardiomyocyte
In cardiomyocytes, the phosphocreatine system also functions as an energy shuttle — transferring high-energy phosphate from the mitochondria (where ATP is produced) to the myofibrils (where it is consumed for contraction) and to the plasma membrane (where it powers ion pumps). The cardiomyocyte is larger than a typical skeletal muscle cell and diffusion of ATP across the cell would be too slow to meet the beat-to-beat contractile demands. Mitochondrial creatine kinase (mtCK) regenerates phosphocreatine from ATP at the mitochondrial membrane; cytosolic creatine kinase (specifically the CK-MM and CK-MB isoforms) regenerates ATP from phosphocreatine at the myofibril and membrane. This shuttle — the phosphocreatine circuit described in the magnesium article — is more important in the cardiomyocyte than in any other cell in the body.
Context: phosphocreatine energy shuttle in cardiomyocytes · mtCK and cytosolic CK isoforms · creatine kinase circuit and cardiac contractile function
II
Cardiac creatine content —
what aging does to it and why that matters.
The cardiac creatine story has been developing in the cardiology and cardiac physiology literature since the 1990s — largely independent of the sport nutrition creatine literature, which has focused overwhelmingly on skeletal muscle. Published studies measuring cardiac creatine content in human post-mortem tissue, in animal models, and increasingly in living humans using ³¹P-MRS have consistently found that cardiac creatine content declines with age — a pattern parallel to the skeletal muscle and brain creatine declines examined in the aging article but with a distinct functional significance given the heart's continuous contractile demands.
The phosphocreatine-to-ATP ratio in the aging heart has been measured in several published ³¹P-MRS studies, with consistent findings of a lower ratio in older compared to younger adults in otherwise comparable populations. This lower ratio reflects reduced phosphocreatine buffer capacity relative to ATP levels — a heart that is, in energetic terms, operating with a narrower safety margin. The functional significance of this reduced buffer is most apparent during demand increases: an aged heart with lower phosphocreatine content has reduced capacity to sustain ATP levels during the rapid demand increase of physical exertion, stress, or tachycardia. Published research has associated lower cardiac phosphocreatine-to-ATP ratios with measures of cardiac functional reserve — the heart's capacity to increase output in response to demand — in aging populations.
The mechanisms driving cardiac creatine decline with age parallel those driving skeletal muscle creatine decline described in the aging article: reduced creatine transporter (SLC6A8) expression in aging cardiomyocytes, reduced creatine kinase activity, and the progressive loss of cardiomyocyte density that accompanies cardiac aging. Unlike skeletal muscle, the heart cannot meaningfully regenerate lost cardiomyocytes — cardiac muscle cells are largely post-mitotic in adults, and the very limited cardiomyocyte renewal that does occur is insufficient to compensate for age-related cell loss. The structural and functional consequences of cardiac aging — including the gradual increase in cardiac stiffness (diastolic dysfunction) and the reduction in maximal cardiac output — are accompanied at the cellular level by these energy metabolism changes whose relationship to each other is an active area of cardiac research.
Creatine Kinase Isoforms · The Cardiac System
Three creatine kinase isoforms operating
in the cardiac energy circuit.
The cardiac creatine kinase system is more complex than its skeletal muscle equivalent — multiple isoforms operating in coordinated fashion to maintain ATP availability across the cardiomyocyte's entire contractile cycle.
Mitochondrial creatine kinase (mtCK) is located on the outer face of the inner mitochondrial membrane, positioned to capture ATP as it exits the mitochondria through the adenine nucleotide translocator and immediately phosphorylate creatine to form phosphocreatine. This positioning makes mtCK the first enzyme the newly synthesized ATP encounters — converting it to phosphocreatine for transport across the cell before it is used at the myofibril. In the cardiomyocyte, mtCK activity is a determinant of how efficiently mitochondrial ATP production is converted into the phosphocreatine that the cytosolic circuit distributes. Reduced mtCK activity — documented in aging cardiac tissue — means less efficient conversion of mitochondrial ATP output into the phosphocreatine that the shuttle depends on. All cited research was conducted independently and did not involve specific Codeage products.
Context: mtCK localization and function · adenine nucleotide translocator coupling · mitochondrial creatine kinase activity in aging heart
CK-MB — the heterodimeric creatine kinase isoform composed of one M subunit and one B subunit — is the predominant cytosolic creatine kinase isoform in adult cardiac muscle. Its cardiac specificity makes it the standard clinical biomarker for myocardial injury — elevated circulating CK-MB is one of the diagnostic indicators examined when cardiac injury is suspected, reflecting its release from damaged cardiomyocytes into the bloodstream. In the normally functioning heart, CK-MB operates at the myofibril and sarcolemma, regenerating ATP from phosphocreatine delivered by the shuttle to sustain continuous contractile activity. CK-MB activity is higher in cardiac than in skeletal muscle, reflecting the heart's greater dependence on the phosphocreatine shuttle for moment-to-moment ATP availability. Age-related reduction in CK-MB activity contributes to the reduced phosphocreatine utilization efficiency of the aging heart.
Context: CK-MB cardiac isoform biology · CK-MB as cardiac biomarker · cytosolic creatine kinase activity in aging cardiomyocytes
CK-MM — the homodimeric isoform consisting of two M subunits — is the dominant creatine kinase isoform in adult skeletal muscle, but is also present in cardiac muscle alongside CK-MB. In the adult heart, the CK-MB to CK-MM ratio is higher than in skeletal muscle — approximately 15–40% CK-MB in cardiac tissue versus less than 1% in most skeletal muscles — reflecting the different functional demands of the two tissue types. During cardiac development, the CK-BB isoform (dominant in fetal cardiac muscle and the brain) transitions to the adult cardiac pattern of CK-MB and CK-MM as cardiomyocytes mature. In failing hearts, a reversion toward a more fetal isoform pattern — with increased CK-BB and reduced total CK activity — has been documented, representing one dimension of the metabolic remodeling that accompanies cardiac dysfunction. The cardiac creatine kinase isoform pattern is thus an indicator not just of enzymatic capacity but of cardiac developmental and disease state.
Context: CK-MM in cardiac muscle · CK isoform ratios in health and disease · creatine kinase remodeling in cardiac pathology
The Cardiac Creatine Numbers
Three figures that frame
the cardiac creatine story.
~30%
Volume fraction of the cardiomyocyte occupied by mitochondria — the highest of any tissue
The cardiac muscle cell's extraordinary mitochondrial density — approximately 30% of cell volume — reflects the heart's near-total dependence on oxidative phosphorylation for ATP supply. This mitochondrial density is the anatomical foundation of the heart's aerobic capacity and the reason the phosphocreatine shuttle — connecting mitochondrial ATP production to myofibrillar consumption across the width of the cell — is more critical in the cardiomyocyte than in any other cell type. The mtCK enzyme's location at the mitochondrial membrane is precisely calibrated for this cellular architecture.
~2:1
Approximate phosphocreatine-to-ATP ratio in the healthy human heart — the energetic safety margin measured by ³¹P-MRS
The phosphocreatine-to-ATP ratio in the healthy adult heart — measurable non-invasively by phosphorus magnetic resonance spectroscopy — is approximately 1.8–2.1 in published studies of healthy young to middle-aged adults. This ratio declines with age and is further reduced in the context of certain cardiac conditions. Published research has associated the magnitude of this decline with measures of cardiac functional reserve — the capacity to increase output in response to demand — making it one of the more informative non-invasive indices of cardiac energetic status available.
100,000×
Approximate number of cardiac contractions per day — each requiring precisely timed ATP delivery from the phosphocreatine system
One hundred thousand beats per day, every day, for a human lifetime of eight or nine decades — totaling approximately 3 billion contractions in a long life. Each contraction requires a precisely timed surge of ATP at the myofibril, delivered via the phosphocreatine shuttle from mitochondria situated micrometers away. The cumulative energetic demand of this continuous work — and the cumulative consequence of a declining phosphocreatine buffer maintaining it — is what distinguishes the cardiac creatine story from any other organ's creatine biology.
III
The heart in the context
of the multi-tissue creatine picture.
The cardiac creatine story is the most consequential of the non-skeletal-muscle creatine stories — the heart's continuous mechanical demands mean that even modest reductions in phosphocreatine buffer capacity have immediate functional significance in ways that comparable reductions in skeletal muscle or brain creatine do not. The ³¹P-MRS research on cardiac energetics has established the phosphocreatine-to-ATP ratio as one of the more sensitive indices of cardiac energetic health available — sensitive enough that changes in this ratio are detectable before clinical symptoms of cardiac functional impairment appear in some study populations.
The connection to the broader multi-tissue framing of this series is direct. The same creatine transporter decline, the same creatine kinase activity reduction, and the same age-related reduction in creatine pool size that drives skeletal muscle creatine loss are operating in the heart simultaneously — but the functional stakes are different. A person whose skeletal muscle creatine content is declining may notice reduced exercise capacity, slower recovery, and reduced muscular power over years. The cardiac parallel operates silently, measurable only through specialized imaging, but contributing to the gradual reduction in cardiac functional reserve that is a consistent feature of the aging heart. The daily consistency framing of creatine as a nutritional input — examined in the longevity article — is supported by the cardiac dimension of the creatine story as much as by the skeletal muscle or brain dimensions, and perhaps more so given the heart's unique status as the one organ that cannot afford intermittent energetic compromise.
The magnesium dimension of this picture is also worth noting. As examined in the dedicated magnesium article, all creatine kinase isoforms — including mtCK and CK-MB — require magnesium as a cofactor, and cardiac ATP is present in cells predominantly as MgATP. The heart's creatine kinase system and its magnesium requirement are inseparable — which is why a formula providing both creatine monohydrate and magnesium is addressing the cardiac energy system's two most directly relevant nutritional inputs simultaneously, in the same daily serving.
Three billion beats in a lifetime.
Each one requiring ATP delivered
via a phosphocreatine shuttle
that quietly declines
across the same decades as everything else.
Codeage · Systemic Balance · Pillar 04
Creatine monohydrate alongside collagen —
daily, for the long arc.
Creatine monohydrate and wild-caught fish collagen peptides, alongside magnesium, hyaluronic acid, vitamin C, and biotin. Two flavors. One daily powder. Formulated without dairy, soy, or gluten. Non-GMO. Manufactured in the USA in a cGMP-certified facility with global ingredients.
Creatine Collagen Peptides — Vanilla Magnesium Biotin
Natural bourbon vanilla. Creatine monohydrate, wild-caught fish collagen peptides I & III, magnesium, hyaluronic acid, vitamin C, biotin. Non-GMO. Made in the USA.
Add to Cart →Creatine Collagen Peptides — Mango Magnesium Biotin
Natural mango flavor. Creatine monohydrate, wild-caught fish collagen peptides I & III, magnesium, hyaluronic acid, vitamin C, and biotin. Made in the USA.
Add to Cart →Codeage · The Longevity Code
A system built for
the long view.
The Longevity Code is a four-pillar daily system — every formula associated with a specific dimension of how the body sustains itself across time.
Explore The Longevity Code →
